
A Phase III International Randomized Controlled Study of Rigosertib Versus Physician's Choice of Treatment in Patients With Myelodysplastic Syndrome After Failure of a Hypomethylating Agent
Recruitment Status
OpenContact the research team to learn more about this study.
Fields marked with asterisk (*) are required